Adam Raymakers
@araymakers.bsky.social
Health economist & research fellow with the Program on Regulation, Therapeutics, & Law (PORTAL) at Harvard Medical School.
Interests: drug pricing/policy, health technology assessment, climate change.
Squamish, BC
www.linkedin.com/in/araymakers
Interests: drug pricing/policy, health technology assessment, climate change.
Squamish, BC
www.linkedin.com/in/araymakers
Pinned
Really excited to share, and happy have been a part of, this new paper led by @wbfeldman.bsky.social out today in @jama.com!
We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US.
Read it here: jamanetwork.com/journals/jam...
We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US.
Read it here: jamanetwork.com/journals/jam...
October 12, 2025 at 1:53 PM
Some more @cnn.com coverage of our study, led by @wbfeldman.bsky.social, on greenhouse gas emissions associated with inhaler use in the US.
October 9, 2025 at 12:47 AM
Some more @cnn.com coverage of our study, led by @wbfeldman.bsky.social, on greenhouse gas emissions associated with inhaler use in the US.
Happy to see that @cnn.com picked up our @jama.com on greenhouse gas emissions and inhaler usage in the US.
Original article: jamanetwork.com/journals/jam...
www.cnn.com/2025/10/06/h...
Original article: jamanetwork.com/journals/jam...
www.cnn.com/2025/10/06/h...
Climate pollution from inhalers has the impact of half a million cars per year, study finds | CNN
The people who are most vulnerable to the hard-to-breathe air that comes with climate change may inadvertently be adding to the problem, new research finds.
www.cnn.com
October 7, 2025 at 11:36 AM
Happy to see that @cnn.com picked up our @jama.com on greenhouse gas emissions and inhaler usage in the US.
Original article: jamanetwork.com/journals/jam...
www.cnn.com/2025/10/06/h...
Original article: jamanetwork.com/journals/jam...
www.cnn.com/2025/10/06/h...
Really excited to share, and happy have been a part of, this new paper led by @wbfeldman.bsky.social out today in @jama.com!
We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US.
Read it here: jamanetwork.com/journals/jam...
We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US.
Read it here: jamanetwork.com/journals/jam...
October 6, 2025 at 8:37 PM
Really excited to share, and happy have been a part of, this new paper led by @wbfeldman.bsky.social out today in @jama.com!
We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US.
Read it here: jamanetwork.com/journals/jam...
We conducted a comprehensive analysis of greenhouse gas emissions associated with inhaler usage in the US.
Read it here: jamanetwork.com/journals/jam...
New edition of the PORTAL Post (the @portalresearch.org monthly newsletter), featuring lots of great research, including our recent publication about modelling the budget impact of gene therapies to treat sickle cell disease in the US.
Check it out here: www.linkedin.com/pulse/octobe...
Check it out here: www.linkedin.com/pulse/octobe...
October 2025 | The future of the FDA, pediatric clinical trials, and the budget impact of sickle cell therapies.
On September 30, PORTAL hosted a symposium on the future of drug regulation at the FDA, featuring conversations with Peter Marks, former Director of the Center for Biologics Evaluation and Research (C...
www.linkedin.com
October 2, 2025 at 5:35 PM
New edition of the PORTAL Post (the @portalresearch.org monthly newsletter), featuring lots of great research, including our recent publication about modelling the budget impact of gene therapies to treat sickle cell disease in the US.
Check it out here: www.linkedin.com/pulse/octobe...
Check it out here: www.linkedin.com/pulse/octobe...
Excited to share new research led by Jessica Harvey exploring the budget impact of gene therapies for sickle cell disease, with a focus on Medicaid programs.
Co-As: @ankurfactorial.bsky.social, @leah-rand.bsky.social, @akesselheim.bsky.social, & George Goshua.
🔗: link.springer.com/article/10.1...
Co-As: @ankurfactorial.bsky.social, @leah-rand.bsky.social, @akesselheim.bsky.social, & George Goshua.
🔗: link.springer.com/article/10.1...
Modeling the Budgetary Impacts of Sickle Cell Disease Gene Therapies on State Medicaid Programs - Journal of General Internal Medicine
Journal of General Internal Medicine -
link.springer.com
September 23, 2025 at 3:15 PM
Excited to share new research led by Jessica Harvey exploring the budget impact of gene therapies for sickle cell disease, with a focus on Medicaid programs.
Co-As: @ankurfactorial.bsky.social, @leah-rand.bsky.social, @akesselheim.bsky.social, & George Goshua.
🔗: link.springer.com/article/10.1...
Co-As: @ankurfactorial.bsky.social, @leah-rand.bsky.social, @akesselheim.bsky.social, & George Goshua.
🔗: link.springer.com/article/10.1...
The Common Sense Oncology Fellowship program is now accepting applications. Definitely a great opportunity for anyone interested in health services research and oncology!
commonsenseoncology.org/wp-content/u...
commonsenseoncology.org/wp-content/u...
commonsenseoncology.org
August 19, 2025 at 2:51 PM
The Common Sense Oncology Fellowship program is now accepting applications. Definitely a great opportunity for anyone interested in health services research and oncology!
commonsenseoncology.org/wp-content/u...
commonsenseoncology.org/wp-content/u...
July 28, 2025 at 4:14 PM
'The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy treatment Elevidys, an HHS official said, in what could be a final blow to the company’s hopes for the product following two patients’ deaths.'
via @endpts.com
endpoints.news/fda-asks-sar...
via @endpts.com
endpoints.news/fda-asks-sar...
Breaking: FDA will ask Sarepta to stop selling Duchenne treatment, following patient deaths
FDA to request Sarepta halt shipments of DMD drug Elevidys after two patient deaths, HHS official says. Trading of $SRPT shares paused after decline.
endpoints.news
July 18, 2025 at 5:53 PM
'The FDA will ask Sarepta to stop shipping its Duchenne muscular dystrophy treatment Elevidys, an HHS official said, in what could be a final blow to the company’s hopes for the product following two patients’ deaths.'
via @endpts.com
endpoints.news/fda-asks-sar...
via @endpts.com
endpoints.news/fda-asks-sar...
'Drugmakers [said] they were stockpiling drugs in the US as a strategy to curb the impact of potential pharma tariffs. In March, Ireland saw a massive 243% increase in pharma exports, compared to the same month last year.'
via @annajbrown.bsky.social / @endpts.com
endpoints.news/pharmaceutic...
via @annajbrown.bsky.social / @endpts.com
endpoints.news/pharmaceutic...
Pharma exports from Ireland climb again as Trump's drug tariffs inch closer
New data from Ireland’s Central Statistics Office suggest that pharmaceutical companies are exporting more inventory to the US as the threat of drug tariffs persists.
endpoints.news
July 17, 2025 at 5:32 PM
'Drugmakers [said] they were stockpiling drugs in the US as a strategy to curb the impact of potential pharma tariffs. In March, Ireland saw a massive 243% increase in pharma exports, compared to the same month last year.'
via @annajbrown.bsky.social / @endpts.com
endpoints.news/pharmaceutic...
via @annajbrown.bsky.social / @endpts.com
endpoints.news/pharmaceutic...
Reposted by Adam Raymakers
July 16, 2025 at 4:13 PM
Always a super interesting read!
Notably, amongst the top 20 CEOs, average compensation was greater than $30 million.
Total compensation for the top 20 CEOs was more than $600,000,000.
Also notable that there is only one woman amongst the top 20.
via @andrewedunn.bsky.social / @endpts.com
Notably, amongst the top 20 CEOs, average compensation was greater than $30 million.
Total compensation for the top 20 CEOs was more than $600,000,000.
Also notable that there is only one woman amongst the top 20.
via @andrewedunn.bsky.social / @endpts.com
July 9, 2025 at 12:57 PM
Always a super interesting read!
Notably, amongst the top 20 CEOs, average compensation was greater than $30 million.
Total compensation for the top 20 CEOs was more than $600,000,000.
Also notable that there is only one woman amongst the top 20.
via @andrewedunn.bsky.social / @endpts.com
Notably, amongst the top 20 CEOs, average compensation was greater than $30 million.
Total compensation for the top 20 CEOs was more than $600,000,000.
Also notable that there is only one woman amongst the top 20.
via @andrewedunn.bsky.social / @endpts.com
Just out! The new guidelines from the Canadian Patented Medicine Prices Review Board (PMPRB) have finally been released. Changes to take effect as of January 2026.
#hta #drugprices
www.canada.ca/en/patented-...
#hta #drugprices
www.canada.ca/en/patented-...
PMPRB releases new Guidelines to monitor and review drug prices - Canada.ca
PMPRB releases new Guidelines to monitor and review drug prices
www.canada.ca
July 2, 2025 at 11:23 PM
Just out! The new guidelines from the Canadian Patented Medicine Prices Review Board (PMPRB) have finally been released. Changes to take effect as of January 2026.
#hta #drugprices
www.canada.ca/en/patented-...
#hta #drugprices
www.canada.ca/en/patented-...
New Health Affairs Forefront by @akesselheim.bsky.social and @jerryavorn.bsky.social from @portalresearch.org about the impact of tariffs on the affordability and availability of medications.
www.healthaffairs.org/content/fore...
www.healthaffairs.org/content/fore...
Trump’s Ongoing Tariff Chaos Will Make Medications Less Affordable And Harder To Find | Health Affairs Forefront
In his first term, Trump made a lot of noise about lowering drug prices but accomplished little of consequence. The noise continues, but it is now accompanied by new ill-conceived initiatives, includi...
www.healthaffairs.org
July 2, 2025 at 8:06 PM
New Health Affairs Forefront by @akesselheim.bsky.social and @jerryavorn.bsky.social from @portalresearch.org about the impact of tariffs on the affordability and availability of medications.
www.healthaffairs.org/content/fore...
www.healthaffairs.org/content/fore...
Reposted by Adam Raymakers
New in @jama.com, Joseph Daval and I discuss legal issues surrounding ACIP including its role in setting government policy and dealing with politically-motivated agendas arising from its new membership: jamanetwork.com/journals/jam...
Legal Challenges for the Advisory Committee on Immunization Practices
This Perspective offers an analysis of the legal foundations in the context of these and other challenges to the role of the Advisory Committee on Immunization Practices.
jamanetwork.com
June 26, 2025 at 7:51 PM
New in @jama.com, Joseph Daval and I discuss legal issues surrounding ACIP including its role in setting government policy and dealing with politically-motivated agendas arising from its new membership: jamanetwork.com/journals/jam...
The clinical aspect & decision aside, it's problematic for health systems that BioMarin priced Brineura at $1 million. If companies didn't charge these prices, decisions would be easier & less restrictive.
Note: Brineura's net sales in 2024 were $170 million (US alone).
www.cbc.ca/news/canada/...
Note: Brineura's net sales in 2024 were $170 million (US alone).
www.cbc.ca/news/canada/...
Vancouver Island family heartbroken as B.C. stops funding $1M drug for girl with terminal condition | CBC News
Charleigh Pollock's mother says the family has gone through a roller-coaster of emotions since learning the B.C. government has pulled funding for the drug their daughter needs for the rare and termin...
www.cbc.ca
June 25, 2025 at 4:40 PM
The clinical aspect & decision aside, it's problematic for health systems that BioMarin priced Brineura at $1 million. If companies didn't charge these prices, decisions would be easier & less restrictive.
Note: Brineura's net sales in 2024 were $170 million (US alone).
www.cbc.ca/news/canada/...
Note: Brineura's net sales in 2024 were $170 million (US alone).
www.cbc.ca/news/canada/...
'A 2023 analysis of more than 20 million deaths across the world found that hot days and days with bad air quality both resulted in higher-than-normal mortality rates. But periods in which heat and pollution are combined were even more deadly.'
via @nytimes.com
via @nytimes.com
Extreme heat & air pollution are a "double whammy" threat to public health, increasing hospital visits for respiratory, heart & mental health, says our director @maryrice-lungdr.bsky.social to @NYTimes.com. Rollbacks to air quality regulations threaten to make pollution worse https://loom.ly/BURs3N0
Extreme Heat Is Exacerbating Air Pollution, a ‘Double Whammy’ for Health
Extreme heat is making air pollution worse, scientists say. And President Trump’s regulatory rollbacks could drive air pollution even higher.
www.nytimes.com
June 24, 2025 at 9:19 PM
'A 2023 analysis of more than 20 million deaths across the world found that hot days and days with bad air quality both resulted in higher-than-normal mortality rates. But periods in which heat and pollution are combined were even more deadly.'
via @nytimes.com
via @nytimes.com
Looking for a recent paper that reports on HRQoL via EQ-5D-5L/3L scores, that specifically reports on the each of the domains/levels of the EQ-5D.
Preferably in a chronic disease, and also preferably US-based (but not necessary). Anyone? @euroqol.bsky.social
#healtheconomics #hspr #QALYs
Preferably in a chronic disease, and also preferably US-based (but not necessary). Anyone? @euroqol.bsky.social
#healtheconomics #hspr #QALYs
June 23, 2025 at 6:31 PM
Looking for a recent paper that reports on HRQoL via EQ-5D-5L/3L scores, that specifically reports on the each of the domains/levels of the EQ-5D.
Preferably in a chronic disease, and also preferably US-based (but not necessary). Anyone? @euroqol.bsky.social
#healtheconomics #hspr #QALYs
Preferably in a chronic disease, and also preferably US-based (but not necessary). Anyone? @euroqol.bsky.social
#healtheconomics #hspr #QALYs
Reposted by Adam Raymakers
Our special issue, “Advancing Trust in Science: Institutional Obligations to Promote Research Integrity,” is now live in @jlme-journal.bsky.social. Check out the full line up of leading voices on spotting, addressing, and preventing misconduct.
www.cambridge.org/core/journal...
www.cambridge.org/core/journal...
June 17, 2025 at 7:54 PM
Our special issue, “Advancing Trust in Science: Institutional Obligations to Promote Research Integrity,” is now live in @jlme-journal.bsky.social. Check out the full line up of leading voices on spotting, addressing, and preventing misconduct.
www.cambridge.org/core/journal...
www.cambridge.org/core/journal...
I've attended this event in the past and it's absolutely fantastic! Not to mention Galway is an incredibly fun city to visit. Highly recommend!
The 5th Ireland Masterclass in Health Economics will take place at @uniofgalway.bsky.social in Galway, Ireland, March 18-20, 2026. For info and to register, visit: blogs.cornell.edu/ireland-mast...
Cc: #Econsky @ashecon.bsky.social @healtheconall.bsky.social
Cc: #Econsky @ashecon.bsky.social @healtheconall.bsky.social
June 17, 2025 at 6:30 PM
I've attended this event in the past and it's absolutely fantastic! Not to mention Galway is an incredibly fun city to visit. Highly recommend!
Added a few more folks recently so thought I'd re-share.
If I've missed you, reach out and I'll add you to the list!
#healtheconomics
If I've missed you, reach out and I'll add you to the list!
#healtheconomics
I've created a #healtheconomics starter pack! There's a few other great packs out there but in this one I've tried to make it more international! 🌎
Let me know if you'd like to be added or if you have recommendations.
And feel free to share!
go.bsky.app/8Lj8FLB
Let me know if you'd like to be added or if you have recommendations.
And feel free to share!
go.bsky.app/8Lj8FLB
June 17, 2025 at 3:20 PM
Added a few more folks recently so thought I'd re-share.
If I've missed you, reach out and I'll add you to the list!
#healtheconomics
If I've missed you, reach out and I'll add you to the list!
#healtheconomics
Super interesting story about Novo Nordisk and their Canadian patents.
'... Novo did file a patent there for semaglutide. . .but the last time they paid the annual maintenance fee on it was 2018!'
by @dereklowe.bsky.social
www.science.org/content/blog...
'... Novo did file a patent there for semaglutide. . .but the last time they paid the annual maintenance fee on it was 2018!'
by @dereklowe.bsky.social
www.science.org/content/blog...
Novo Nordisk's Canadian Mistake
www.science.org
June 16, 2025 at 3:13 PM
Super interesting story about Novo Nordisk and their Canadian patents.
'... Novo did file a patent there for semaglutide. . .but the last time they paid the annual maintenance fee on it was 2018!'
by @dereklowe.bsky.social
www.science.org/content/blog...
'... Novo did file a patent there for semaglutide. . .but the last time they paid the annual maintenance fee on it was 2018!'
by @dereklowe.bsky.social
www.science.org/content/blog...
Great and engaging panel discussion about the future of the Inflation Reduction Act by @benro.me and Chris Cai (both from @portalresearch.org), @dusetzinas.bsky.social (Vanderbilt Health Policy), and Alyson Bancroft (@p4ad.bsky.social)!
#ARM25
#ARM25
June 9, 2025 at 11:02 PM
Great and engaging panel discussion about the future of the Inflation Reduction Act by @benro.me and Chris Cai (both from @portalresearch.org), @dusetzinas.bsky.social (Vanderbilt Health Policy), and Alyson Bancroft (@p4ad.bsky.social)!
#ARM25
#ARM25
Presenting some work on spending associated with drugs for ultra-rare diseases at the @academyhealth.bsky.social
Annual Research Meeting!
#arm25 @portalresearch.org
Annual Research Meeting!
#arm25 @portalresearch.org
June 9, 2025 at 2:15 PM
Presenting some work on spending associated with drugs for ultra-rare diseases at the @academyhealth.bsky.social
Annual Research Meeting!
#arm25 @portalresearch.org
Annual Research Meeting!
#arm25 @portalresearch.org